Financials
Thermo Fisher Scientific (TMO) Financial Statements: Income, Balance Sheet & Cash Flow
Revenue, profitability, balance-sheet strength, and cash generation for TMO. SEC filings, statements through Jun 27, 2026.
Section freshness
Prices as of Sep 17, 11:12 AM EDT · Fundamentals checked Sep 17, 11:12 AM EDT · Statements Jun 27, 2026
Financial read
TMO latest financial snapshot.
Start with the latest reported values below. Deeper quarterly and annual statement tables follow when supplied.
Revenue
$11.99B
+10.5% YoY
Net income
$1.74B
+5.1% QoQ
Free cash flow
$1.68B
+105.3% QoQ
Net margin
14.47%
Operating margin 17.40%
Balance sheet coverage
TMO balance sheet summary
Assets, liabilities, liquidity, debt, and equity sit beside income and cash-flow tables so the statement history reads as one model-ready dataset.
20 quarterly · 4 annual rows · Market data source · as of 2026-06-27
Latest period
Q2 FY2026
20 quarterly · 4 annual rows
Assets / liabilities
$113.17B
Liabilities —
Cash / debt
$4.06B
Net cash $696.00M
Equity / working capital
$52.68B
Working capital $8.30B
Financial statements
TMO statement coverage.
Income statement, balance sheet, and cash-flow figures for TMO, with quarterly and annual history in the tables below.
Data last updated
Jun 26, 2026
Income periods
24
Balance-sheet periods
24
Cash-flow periods
24
Quarterly and annual TMO statements, sourced from SEC filings, statements through Jun 27, 2026.
Financial statement period
TMO statement history
SEC filings, statements through Jun 27, 2026 · Data last updated: Jun 26, 2026
Income statement
Quarterly and annual rows for revenue, operating leverage, earnings quality, and margin direction.
| Period | Revenue | Operating income | Net income | Net margin | Revenue QoQ | Net income QoQ |
|---|---|---|---|---|---|---|
| Q2 FY2026 | $11.99B | $2.09B | $1.74B | 14.47% | +9.0% | +5.1% |
| Q1 FY2026 | $11.01B | $1.86B | $1.65B | 15.00% | -9.9% | -15.9% |
| Q4 FY2025 | $12.21B | $2.25B | $1.96B | 16.08% | +9.8% | +21.5% |
| Q3 FY2025 | $11.12B | $1.94B | $1.62B | 14.53% | +2.5% | -0.1% |
| Q2 FY2025 | $10.86B | $1.83B | $1.62B | 14.90% | +4.7% | +7.3% |
| Q1 FY2025 | $10.36B | $1.72B | $1.51B | 14.54% | -9.0% | |
| Q4 FY2024 | $11.39B | $2.02B | +7.5% | |||
| Q3 FY2024 | $10.60B | $1.84B | $1.63B | 15.38% | +0.5% | +5.3% |
Balance sheet
Balance-sheet history for assets, liabilities, liquidity, debt, equity, and shares outstanding.
| Period | Cash | Current assets | Current liabilities | Total assets | Total debt | Total equity | Debt QoQ |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 | $4.06B | $23.36B | $15.07B | $113.17B | $3.37B | $52.68B | +9.0% |
| Q1 FY2026 | $3.25B | $22.32B | $14.62B | $113.28B | $3.09B | $51.93B | -12.5% |
| Q4 FY2025 | $9.85B | $28.71B | $15.19B | $110.34B | $3.53B | $53.41B | -7.6% |
| Q3 FY2025 | $1.98B | $22.30B | $14.89B | $103.02B | $3.82B | $51.02B | +72.7% |
| Q2 FY2025 | $4.58B | $24.58B | $12.72B | $101.23B | $2.21B | $50.51B | -21.5% |
| Q1 FY2025 | $4.13B | $23.38B | $13.17B | $99.04B | $2.82B | $49.39B | +27.3% |
| Q4 FY2024 | $4.01B | $22.14B | $13.33B | $97.32B | $2.21B | $49.58B | -46.2% |
| Q3 FY2024 | $4.64B | $23.78B | $14.60B | $100.36B | $4.12B | $48.99B | -19.6% |
Cash flow
Operating cash generation, capital expenditure, free cash flow, buybacks, dividends, and cash movement.
| Period | Operating cash flow | CapEx | Free cash flow | Net income | Dividends paid | Buybacks | FCF QoQ |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 | $2.13B | $450.00M | $1.68B | $1.74B | $175.00M | $1.00B | +105.3% |
| Q1 FY2026 | $1.19B | $376.00M | $816.00M | $1.65B | $162.00M | $3.00B | -72.7% |
| Q4 FY2025 | $3.46B | $465.00M | $2.99B | $1.96B | $162.00M | $37.00M | +63.1% |
| Q3 FY2025 | $2.24B | $404.00M | $1.83B | $1.62B | $163.00M | $963.00M | +66.1% |
| Q2 FY2025 | $1.40B | $294.00M | $1.10B | $1.62B | $162.00M | — | +206.1% |
| Q1 FY2025 | $723.00M | $362.00M | $361.00M | $1.51B | $149.00M | $2.00B | -87.2% |
| Q4 FY2024 | $3.29B | $480.00M | $2.81B | $149.00M | $1.00B | +48.4% | |
| Q3 FY2024 | $2.17B | $272.00M | $1.89B | $1.63B | $150.00M | — | +14.2% |
Valuation and returns
- Enterprise value
- $241.03B
- TECHi computed
- Return on equity
- 13.23%
- Market data source · as of 2026-09-17
- Return on assets
- 6.16%
- Market data source · as of 2026-09-17
- Debt / equity
- 0.06
- Current ratio 1.55
Ratio values use provider-attributed fields when available and otherwise fall back to TECHi statement math from the visible rows on this page.
Annual revenue and income multiples
Annual sales and income multiple reads use the latest annual statement when available, then fall back to trailing-twelve-month statement math from the visible quarterly rows.
- Annual revenue base
- $44.56B
- Annual statement 2025-12-31
- Annual income base
- $6.70B
- Annual statement 2025-12-31
- Market cap / annual revenue
- 5.43
- Live market value divided by annual revenue
- Market cap / annual income
- 36.06
- Live market value divided by annual net income
Annual sales and income multiple
Market capitalization bridge
TTM valuation multiples
- TTM revenue
- $46.34B
- Trailing twelve months
- TTM EBIT
- $8.15B
- TTM operating income
- Market cap / TTM revenue
- 5.22
- Live market value divided by trailing twelve months revenue
- EV / TTM revenue
- 5.20
- Enterprise value divided by trailing twelve months revenue
Live market value is matched against trailing-twelve-month statement bases first so the multiple moves with the tape instead of anchoring to stale fiscal-year rows.
Profit multiples
Revenue, net income, and free cash flow
Quarterly statement rows, shown on one common dollar scale so margin compression and cash conversion stand out quickly.
Efficiency
- Revenue / employee
- $370,688
- 125,000 employees
- Net income / employee
- $55,736
- TTM net income divided by employees
- FCF / employee
- $58,544
- TTM free cash flow divided by employees
- Market cap / employee
- $1.93M
- Live value per employee
Growth vs cost pressure
Cash conversion
TTM free cash flow / TTM operating income
Quarterly margin heatmap
Latest quarter expense mix
Profit bridge
Other income statement lines
Balance sheet · Q2 FY2026
- Cash & equivalents
- $4.06B
- Total debt
- $3.37B
- Net cash
- $696.00M
- Net cash position
- Total equity
- $52.68B
Balance sheet detail
- Current assets
- $23.36B
- Current liabilities
- $15.07B
- Inventory
- $5.63B
- Receivables
- $9.45B
- Property, plant & equipment
- $10.76B
- Current debt
- $3.37B
Debt and liquidity
Cash + short-term investments + receivables / current liabilities
Cash generation
- Operating cash flow
- $2.13B
- Capital expenditure
- $450.00M
- Free cash flow
- $1.68B
- Capital returned
- $1.18B
- Buybacks + dividends paid
Cash-flow detail
- Investing cash flow
- $164.00M
- Financing cash flow
- -$1.57B
- Buybacks
- $1.00B
- Net buybacks
- $1.00B
- Repurchases less stock issuance
- Dividends paid
- $175.00M
Cash flow read
TMO converts most of its earnings into cash.
Free cash flow of $1.68B versus $1.74B of reported net income means accruals aren't doing much heavy lifting — the cash is showing up alongside the earnings. That's the cleanest profile a fundamentals desk wants to see.
Frequently asked
Common questions.
What financial data is available for TMO?
TECHi shows Thermo Fisher Scientific's income statement, balance sheet, and cash-flow statement by reported period, with each figure attributed to its source. Line items the company does not report are left blank rather than estimated.
How current are TMO's financial statements?
Each TMO statement is labelled with its reported period and source, so you can see exactly which quarter or fiscal year a figure covers and when the data was last updated.
What is Thermo Fisher Scientific's reported net margin?
Thermo Fisher Scientific reports a net margin of 15.04% in its latest available fundamentals; the statements below show the revenue and cost lines behind it.